Printer Friendly

STAAR ANNOUNCES FIRST RUSSIAN IMPLANTABLE CONTACT LENS COURSE

 MONROVIA, Calif., July 7 /PRNewswire/ -- STAAR Surgical Company (NASDAQ: STAA) announced today the completion of its first advanced ocular surgery training course conducted in Moscow, Russia. The three- day course introduced 23 leading American and European surgeons to revolutionary techniques for treating adults with near-sightedness (myopia) and far-sightedness (hyperopia) as well as people suffering from glaucoma.
 The course was hosted by STAAR Surgical Company, Eye Microsurgery Intersectoral Research and Technology (MNTK) and the noted Russian ophthalmologist Professor Svyatoslov Fyodorov, M.D. Fyodorov is noted for originally developing the procedure known as "Radial Keratotomy" (RK) which corrects normal refractive problems of the eye. His latest innovation, the "Implantable Contact Lens" (ICL) has been developed in conjunction with STAAR's Research and Development department. The ICL consists of a new type of lens that is placed inside the eye to permanently correct myopia and hyperopia.
 Ophthalmologist Harry Grabow, M.D. of Sarasota, Fla., who attended the training course said, "This is the first time that American eye surgeons have been able to observe the surgical implantation of the ICL and to examine patients at various postoperative stages. The clinical results are really very exciting. With STAAR's advanced lens technology, the ICL could be a significant development for virtually anyone who wears glasses or contact lenses."
 Course participants were also introduced to a new device for the treatment of glaucoma, a debilitating eye disease that is the leading cause of blindness. Dr. Manus Kraff of Chicago, another course attendee said, "It could very well render eye drops, which are very expensive, obsolete for most types of glaucoma."
 John R. Shepherd, M.D. of Las Vegas, STAAR's medical monitor noted, "It would have been hard to imagine this level of cooperation between Russian and American ophthalmologists just a few short years ago. It's very exciting."
 "We have already begun the regulatory process for introducing these devices in the United States," said John R. Wolf, president and CEO of STAAR Surgical Company. "The glaucoma device will probably be sold in the U.S. within six to nine months, but the ICL will need a few years of clinical studies. However, as part of STAAR's strategy to increase its international sales efforts, we plan to begin training doctors and selling both products outside the U.S. almost immediately."
 STAAR Surgical Company, a publicly traded company founded in 1982, develops, manufactures and markets products for micro incision ophthalmic surgery, primarily for use in cataract procedures. All of STAAR's primary products are approved by the FDA.
 -0- 7/7/93
 /CONTACT: William Roberts (investor relations) of Cameron Towey Central, 513-469-0202, or Jane Ingalls (media relations) of Sawyer/Miller Group, 212-484-7558; both for STAAR Surgical Company/
 (STAA)


CO: STAAR Surgical Company ST: California IN: MTC SU:

BM -- CL003 -- 8952 07/07/93 09:18 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 7, 1993
Words:465
Previous Article:CHARTER FEDERAL ANNOUNCES EARNINGS OF $2.2 MILLION FOR THE FOURTH QUARTER OF FISCAL 1993
Next Article:MOSLER TO PURCHASE SECURITY CONTROL SYSTEMS
Topics:


Related Articles
STAAR SURGICAL NAMES NEW EXECUTIVE TO TOP POST
STAAR SURGICAL COMPANY ANNOUNCES AUSTRALIAN APPROVAL; CONFERENCE CALL WITH BROKERS PLANNED TODAY
STAAR SURGICAL RESPONDS TO MEDICARE CUTS; CHAIRMAN STATES CUTS WILL NOT ADVERSELY AFFECT STAAR
STAAR SURGICAL FIRST QUARTER NET INCOME UP 45 PERCENT; REVENUES UP 26 PERCENT
STAAR SURGICAL REPORTS 10TH CONSECUTIVE QUARTER OF DOUBLE DIGIT YEAR-OVER-YEAR SALES/EARNINGS INCREASES
STAAR SURGICAL REPORTS RECORD RESULTS FOR THE THIRD CONSECUTIVE YEAR
STAAR SURGICAL FIRST QUARTER PRE-TAX INCOME UP 35 PERCENT; REVENUES UP 3O PERCENT
STAAR SURGICAL COMPANY AND ALCON LABORATORIES SETTLE PATENT INFRINGEMENT AND LICENSE DISPUTE
STAAR SURGICAL REPORTS RECORD SECOND QUARTER REVENUES AND PRE-TAX EARNINGS
STAAR Surgical Reports Third Quarter

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters